PipeBio alternatives
TL;DR: 12 companies doing similar work to PipeBio in Healthcare, ranked by how closely they match what PipeBio actually does — not just by category.
How this list was built: every company here is Y Combinator-backed and shares at least one category with PipeBio. They are scored on how closely their own description overlaps with PipeBio's, and all facts shown come from the YC company records — nothing is estimated.
What are the best alternatives to PipeBio?
| Alternative | What it does | Batch | Team | Status |
|---|---|---|---|---|
| Mind Emulation Foundation | — | Winter 2018 | 1 | Active |
| Excepgen | — | Winter 2019 | 3 | Active |
| ResistanceBio | We solve drug resistance for cancer | Winter 2019 | 15 | Inactive |
| Atlas Discovery | AI-native pharma company | Summer 2026 | 3 | Active |
| Verge Genomics | We use human data and AI to develop better drugs faster. | Summer 2015 | 50 | Active |
| Inflow | A self-help app for people to manage their ADHD. | Summer 2021 | 20 | Acquired |
| Care GP | AI agents to run primary healthcare operations | Summer 2026 | 10 | Active |
| Circumvent | Utilizing monogenic disorders to inform and solve highly complex… | Summer 2018 | 6 | Active |
| Gerostate Alpha | Developing novel therapeutics for aging and chronic disease | Summer 2018 | 6 | Inactive |
| Nuntius Therapeutics | Cell-specific genetic medicines | Winter 2021 | 2 | Active |
| Ochre Bio | RNA medicines for liver diseases | Winter 2020 | 50 | Active |
| Velorum Therapeutics | Breakthrough medicines unlocking the biology of heme | Winter 2024 | 5 | Active |
Is PipeBio still active?
PipeBio has been acquired, which often means pricing, roadmap or support changes. That is the usual reason people start looking at this list.
How was this list put together?
Every company here is Y Combinator-backed and shares at least one category with PipeBio. They are then ranked on how closely their own description overlaps with PipeBio's, so the closest matches come first rather than whoever happens to share a tag.